Azole endothelin antagonists. 3. Using Δ log P as a tool to improve absorption

Journal of Medicinal Chemistry

Volumn 39, Issue 4, 1996, Pages 982-991

  Von Geldern, Thomas W ^b   Hoffman, Daniel J ^a   Kester, Jeffrey A ^b   Nellans, Hugh N ^a   Dayton, Brian D ^b   Calzadilla, Samuel V ^b   Marsh, Kennan C ^a   Hernandez, Lisa ^a   Chiou, William ^b   Dixon, Douglas B ^b   Wu Wong, Jinshyun R ^b   Opgenorth, Terry J ^b  

^a ABBOTT LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; ENDOTHELIN RECEPTOR ANTAGONIST; PYRROLE DERIVATIVE;

ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SYNTHESIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PROTEIN MODIFICATION; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ADMINISTRATION, ORAL; ANIMALS; AZEPINES; AZOLES; DRUG DESIGN; HYDROGEN BONDING; INDICATORS AND REAGENTS; INDOLES; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; KINETICS; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 13344277282     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9505932     Document Type: Article

References (17)

1. von Geldern, T. W.; Hutchins, C. W.; Kester, J. A.; Wu-Wong, J. R.; Chiou, W.; Dixon, D. B.; Opgenorth, T. J. J. Med. Chem. 1996, 39, 957-967.
2. von Geldern, T. W.; Kester, J. A.; Bal, R.; Wu-Wong, J. R.; Chiou, W.; Dixon, D. B.; Opgenorth, T. J. J. Med. Chem. 1996, 39, 968-981.
3. See: Burton, P. S.; Conradi, R. A.; Hilgers, A. R. (B) Mechanisms of Peptide and Protein Absorption. (2) Transcellular Mechanisms of Peptide and Protein Absorption: Passive Aspects. Adv. Drug Del. Rev. 1991, 7, 365-386 for an excellent review of the problem, and for further references.
4. Seiler, P. Interconversion of Lipophilicities from Hydrocarbon/ water Systems into the Octanol/water System. Eur. J. Med. Chem. 1974, 9, 473-479.
5. Conradi, R. A..; Hilgers, A. R.; Ho, N. F. H.; Burton, P. S. The Influence of Peptide Structure on Transport Across Caco-2 Cells. Pharm. Res. 1991, 8, 1453-1460. Conradi, R. A.; Hilgers, A. R.; Ho, N. F. H.; Burton, P. S. The Influence of Peptide Structure on Transport Across Caco-2 Cells. II. Peptide Bond Modification Which Results in Improved Permeability. Pharm. Res. 1992, 9, 435-439.
6. Conradi, R. A..; Hilgers, A. R.; Ho, N. F. H.; Burton, P. S. The Influence of Peptide Structure on Transport Across Caco-2 Cells. Pharm. Res. 1991, 8, 1453-1460. Conradi, R. A.; Hilgers, A. R.; Ho, N. F. H.; Burton, P. S. The Influence of Peptide Structure on Transport Across Caco-2 Cells. II. Peptide Bond Modification Which Results in Improved Permeability. Pharm. Res. 1992, 9, 435-439.
7. 2 Receptor Histamine Antagonists. J. Med. Chem. 1988, 31, 656-671. Chikale, E. G.; Ng, K.-Y.; Burton, P. S.; Borchardt, R. T. Hydrogen Bonding Potential as a Determinant of the in Vitro and in Situ Blood-Brain Barrier Permeability of Peptides. Pharm. Res. 1994, 11, 412-419.
8. 2 Receptor Histamine Antagonists. J. Med. Chem. 1988, 31, 656-671. Chikale, E. G.; Ng, K.-Y.; Burton, P. S.; Borchardt, R. T. Hydrogen Bonding Potential as a Determinant of the in Vitro and in Situ Blood-Brain Barrier Permeability of Peptides. Pharm. Res. 1994, 11, 412-419.
9. Benet, L. Z.; Sheiner, L. B. Design and Optimization of Dosage Regimens; Pharmacokinetic Data. In The Pharmacological Basis of Therapeutics; Gilman, A. G., Goodman, L. S., Rall, T. W., Murad, F., Eds.; Macmillan Publishing Co.: New York, 1985; p 1709.
10. Winn, M.; De, B.; Zydowsky, T. M.; Altenbach, R. J.; Basha, F. Z.; Boyd, S. A.; Brune, M. E.; Buckner, S. A.; Crowell, D.; Drizin, I.; Hancock, A. A.; Jae, H.-S.; Kester, J. A.; Lee, J. Y.; Mantei, R. A.; Marsh, K. A.; Novosad, E. I.; Oheim, K. W.; Rosenberg, S. H.; Shiosaki, K.; Sorensen, B. K.; Spina, K.; Sullivan, G. M.; Tasker, A. S.; von Geldern, T. W.; Warner, R. B.; Opgenorth, T. J.; Kerkman, D. J.; DeBernardis, J. F. 2-(Alkylamino)nicotinic Acid and Analogs. Potent Angiotensin II Antagonists. J. Med. Chem. 1993, 36, 2676-2688.
11. Clozel, M.; Breu, V.; Burri, K.; Cassal, J.-M.; Fischli, W.; Gray, G. A.; Hirth, G.; Loffler, B.-M.; Müller, M.; Neidhart, W.; Ramuz, H. Pathophysiological Role of Endothelin Revealed by the First Orally Active Endothelin Receptor Antagonist. Nature 1993, 365, 759-761.
12. Plattner, J. J.; Marcotte, P. A.; Kleinert, H. D.; Stein, H. H.; Greer, J.; Bolis, G.; Fung, A. K. L.; Bopp, B. A.; Luly, J. R.; Sham, H. L.; Kempf, D. J.; Rosenberg, S. H.; Dellaria, J. F.; De, B.; Merits, I.; Perun, T. J. Renin Inhibitors. Dipeptide Analogues of Angiotensinogen Utilizing a Structurally Modified Phenylalanine Residue to Impart Proteolytic Stability. J. Med. Chem. 1988, 31, 2277-2288.
13. Rosenberg, S. H.; Woods, K. W.; Kleinert, H. D.; Stein, H.; Nellans, H. N.; Hoffman, D. J.; Spanton, S. G.; Pyter, R. A.; Cohen, J.; Egan, D. A.; Plattner, J. J.; Perun, T. J. Azido Glycols: Potent, Low Molecular Weight Renin Inhibitors Containing an Unusual Post Scissile Site Residue. J. Med. Chem. 1989, 32, 1371-1378.
14. Yamada, S.-I.; Shioiri, T.; Itaya, T.; Hara, T.; Matsueda, R. Ind.-N-Alylation of Tryptophan and Synthesis of 1-Alkyltryptophan Hydrazides. Chem. Pharm. Bull. 1965, 13, 88-93.
15. Cheung, S. T.; Benoiton, N. L. N-Methylamino Acids in peptide synthesis. V. The Synthesis of N-tert-butoxycarbonyl, N-Methyl-amino Acids by N-Methylation. Can. J. Chem. 1977, 55, 906-910.
16. Statistical Consultants, Inc. PCNONLIN and NONLIN84: Software for the Statistical Analysis of Nonlinear Models. Am. Statistician 1986, 40, 52.
17. Sedman, A. J.; Wagner, J. G. CSTRIP - A FORTRAN Computer Program for Obtaining Initial Polyexponential Estimates. J. Pharm. Sci. 1976, 65, 1006-1010.